कंपनी का अवलोकन
AIM ImmunoTech Inc. is an immuno-pharma entity dedicated to the research and development of therapeutics designed to treat multiple types of cancers, viral diseases, and immune-deficiency disorders within the United States. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant investment in R&D before commercialization. Its current scale is defined by a market capitalization of $4.22 million, annual revenue of $88,000, and an employee count of 19. These figures indicate that the company is in a very early-stage development phase with minimal operational footprint, suggesting that its valuation relies heavily on the potential of its pipeline rather than established earnings power or large-scale commercial operations.
वित्तीय स्वास्थ्य
The company reported revenue of $88,000 for the trailing twelve months, accompanied by a net income of $-13,958,000 and an EBITDA of $-11,454,000. The substantial gap between the nominal revenue and the significant net loss reveals a cost structure dominated by heavy research and development expenditures or operational inefficiencies that far exceed current sales generation. Free cash flow stands at $-11,966,500, indicating that the company is burning cash rapidly and lacks the immediate financial flexibility to fund operations without external capital injections or equity dilution. The gross margin is reported at -45.5%, the operating margin at -14057.1%, and the profit margin at 0.0%, all of which reflect the pre-revenue or loss-making status typical of early-stage biotechnology firms where costs are incurred before products generate sufficient volume. The company holds $3.05 million in cash against $4.90 million in debt, while the debt-to-equity ratio is listed as N/A due to the absence of positive equity in traditional calculations. This balance sheet configuration suggests a leveraged position relative to its asset base, yet the negative equity complicates standard leverage interpretations. The current ratio is 0.53, which indicates that the company possesses only 53 cents in liquid assets for every dollar of current liabilities, signaling potential short-term liquidity challenges. Return on Equity is N/A and Return on Assets is -101.3%, revealing that management is currently destroying shareholder value and that asset utilization is generating significant losses relative to the capital employed.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is N/A, while the forward P/E is -0.12, a disparity that implies the market is pricing in expected future earnings recovery or continued losses rather than current profitability. The price-to-book ratio is -0.16, indicating that the stock trades at a significant discount to its book value, a common characteristic for speculative biotechnology assets with intangible value not captured on the balance sheet. The price-to-sales ratio is 47.96, and the EV/EBITDA is -0.53, suggesting that the market values the company primarily on its revenue potential and intellectual property rather than earnings multiples. The stock has a 52-week high of $19.74 and a 52-week low of $0.51, meaning the current trading price sits significantly below the annual high, reflecting high volatility and investor skepticism regarding near-term commercial viability. The beta value is 1.36, which indicates that the stock price is expected to be 36% more volatile than the broader market, amplifying both potential gains and losses in response to sector-specific news or market movements.
Growth & Income
Revenue growth year-over-year is -53.3%, while earnings growth is N/A, demonstrating that the company is contracting in terms of sales and has not yet achieved consistent profitability to measure earnings expansion. Since earnings are negative, they cannot grow faster than revenue in a traditional sense, implying the company is still in a phase of scaling operations or reducing costs before reaching a break-even point. As a non-dividend payer, the company currently reinvests its limited resources into growth initiatives rather than distributing cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. The overall growth and income profile is characterized by negative revenue trajectories and a complete absence of income generation, typical for a micro-cap biotechnology firm in the research and development stage.